Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Tonghua Dongbao Doses First Patient in China Phase III Trial of Ultra-Rapid Insulin

publication date: May 10, 2022

Tonghua Dongbao Pharma has dosed the first person in a China Phase III trial of an Ultra-Rapid insulin developed by Adocia of Lyon, France. The trial will enroll 1300 people with type 1 and type 2 diabetes in 100 China sites. As part of a two-drug deal,, Tonghua Dongbao in-licensed China and South-East Asia rights to BioChaperone® Lispro from Adocia for $10 million upfront and $35 million in milestones, plus royalties. The second Adocia diabetes therapy in the deal is a fixed-ratio glargine and lispro combination. More details....

Stock Symbols: (SHA: 600867) (Paris: ADOC)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.